- Home
- SYF vs BIIB Comparison
SYF vs BIIB Comparison
Compare SYF & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYF
- BIIB
- Stock Information
- Founded
- SYF 1932
- BIIB 1978
- Country
- SYF United States
- BIIB United States
- Employees
- SYF N/A
- BIIB N/A
- Industry
- SYF Finance: Consumer Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- SYF Finance
- BIIB Health Care
- Exchange
- SYF Nasdaq
- BIIB Nasdaq
- Market Cap
- SYF 20.3B
- BIIB 19.9B
- IPO Year
- SYF N/A
- BIIB 1991
- Fundamental
- Price
- SYF $57.61
- BIIB $131.20
- Analyst Decision
- SYF Buy
- BIIB Buy
- Analyst Count
- SYF 21
- BIIB 26
- Target Price
- SYF $62.00
- BIIB $194.95
- AVG Volume (30 Days)
- SYF 3.7M
- BIIB 1.7M
- Earning Date
- SYF 07-16-2025
- BIIB 05-01-2025
- Dividend Yield
- SYF 2.08%
- BIIB N/A
- EPS Growth
- SYF 4.77
- BIIB 26.39
- EPS
- SYF 7.27
- BIIB 10.12
- Revenue
- SYF $8,705,000,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- SYF $97.32
- BIIB N/A
- Revenue Next Year
- SYF $5.21
- BIIB N/A
- P/E Ratio
- SYF $7.93
- BIIB $12.83
- Revenue Growth
- SYF 0.44
- BIIB 1.59
- 52 Week Low
- SYF $40.55
- BIIB $110.04
- 52 Week High
- SYF $70.93
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- SYF 54.22
- BIIB 59.82
- Support Level
- SYF $55.67
- BIIB $123.97
- Resistance Level
- SYF $59.20
- BIIB $132.94
- Average True Range (ATR)
- SYF 1.31
- BIIB 3.49
- MACD
- SYF -0.32
- BIIB 1.04
- Stochastic Oscillator
- SYF 32.44
- BIIB 88.37
About SYF Synchrony Financial
Synchrony Financial, originally a spinoff of GE Capital's retail financing business, is the largest provider of private-label credit cards in the United States by both outstanding receivables and purchasing volume. Synchrony partners with other firms to market its credit products in their physical stores as well as on their websites and mobile applications. Synchrony operates through three segments: retail card (private-label and co-branded general-purpose credit cards), payment solutions (promotional financing for large ticket purchases), and CareCredit (financing for elective healthcare procedures).
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.